Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Page 8 of 16
Jun 26, 2026The acquisition of Bio-Techne by Merck KGaA for $11 billion represents one of 2026’s most significant biopharma moves, positioning Merck squarely at the forefront of cell therapy innovation. This deal highlights a shifting landscape as companies seek to secure advanced manufacturing technologies and fortify their pipeline.
Jun 26, 2026A recent human embryo study highlights breakthroughs in the accuracy of next-generation CRISPR tools, providing insight into early-stage developmental processes. At the same time, these innovations raise profound questions about the responsible application of gene editing and the potential societal consequences of altering the human germline.
Jun 24, 2026The experimental psychedelic ibogaine has drawn significant attention as an unapproved treatment for substance use disorder (SUD). While many clinicians remain skeptical of its efficacy and safety, they nevertheless face new responsibilities as some patients pursue this unconventional route. Examining ibogaine's signal, risk profile, and the evolving role of providers in the changing landscape of SUD care.
Jun 23, 2026In a notable move expanding the transpacific scope of biotech dealmaking, New Jersey’s Nuvectis and China’s Haisco Pharmaceutical have entered an agreement that could be worth up to $1.4 billion. The deal, focused on two late-stage assets, illustrates how licensure partnerships and international alliances are becoming indispensable as companies navigate complex global pipelines.
Jun 22, 2026As the role of monoclonal antibodies expands in healthcare, nations and health systems are re-evaluating their preventive medicine strategies. The precision, adaptability, and growing uptake of this approach mark a significant departure from historical paradigms.
Jun 21, 2026Backed by top-tier investors and led by seasoned industry professionals, cAMPfield Therapeutics aims to radically rethink approaches to inflammatory bowel disease. With strong financial traction in its first round, the biotech start-up is advancing new clinical programs with the potential to address profound unmet needs in IBD.
Jun 21, 2026Biotech start-up Cambrian’s latest development—a drug that reportedly mimics the effects of physical exercise—raises major questions about the future of aging, disease prevention, and the intersection of biotechnology with lifestyle interventions. Early reports prompt both excitement and skepticism within the medical and scientific communities.
Jun 19, 2026New biotech player Memento has secured substantial early-stage funding and picked up a bispecific antibody that both blocks VEGF and activates Tie2, poised to enter clinical trials for multiple retinal conditions. The company’s efforts highlight renewed investor confidence in innovative approaches for eye diseases with significant unmet needs.
Jun 19, 2026The U.S. Food and Drug Administration’s advisers have cast their support behind Moderna’s experimental mRNA flu vaccine. This milestone places Moderna at the forefront of a new era in influenza vaccine technology, yet it also reflects the ongoing tension over novel vaccine evaluation and approval.
Jun 17, 2026The termination of Be Biopharma’s hemophilia B cell therapy trial underscores the persistent scientific and commercial challenges in advancing novel therapies for hemophilia. This development adds to a growing list of recent withdrawals in the field and raises broader questions for biotech companies and investors navigating unmet needs and competitive dynamics in rare disease drug development.
Jun 17, 2026The latest $27 million financing for MultiValent Biotherapies represents a significant advance for dual-targeting prostate cancer therapies. The company’s clinical-stage asset utilizes a peptide conjugate designed to simultaneously target both PSMA and folate receptor alpha, aiming to overcome resistance and improve outcomes for patients with advanced prostate cancer.
Jun 12, 2026In a notable advance for genetic medicines and rare diseases, Novartis reports that its investigational RNA therapy, del-brax, has met primary goals in a Phase 1/2 clinical trial for facioscapulohumeral muscular dystrophy (FSHD). Coming out of Novartis’ $12 billion acquisition of Avidity Biosciences, this development signals important milestones for patients, the company, and the broader future of RNA therapeutics targeting previously untreatable disorders.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.